Proteomics International (ASX:PIQ) and Eurobio Scientific to sell PromarkerD Predictive Diabetic Kidney Disease Test in France
Price Sensitive Announcement $
Overview:
Proteomics International Laboratories Ltd, a pioneer in predictive diagnostics announced that Eurobio Scientific has been appointed to distribute its PromarkerD predictive test for diabetic kidney disease in France.
Eurobio Scientific (EPA:ALERS) is a leading French company in the fields of in vitro diagnostics (IVD), life
sciences, and biotechnology, and specialises in developing, manufacturing, and distributing diagnostic
products and services. Eurobio Scientific has a proven track record of marketing speciality diagnostic tests topublic and private clinical laboratories, and is currently the leading independent distributor of IVDs in
France.
Keynotes:
Proteomics International has engaged with Eurobio Scientific for the exclusive distribution of the PromarkerD predictive test for diabetic kidney disease in France
Eurobio Scientific (EPA:ALERS) has a proven track record of marketing speciality diagnostic tests to public and private clinical laboratories
Eurobio Scientific is currently the leading independent distributor of in-vitro diagnostics (IVD) in France where 3.9 million people or 8.6 per cent of the adult population live with diabetes
France has one of the highest rates of end-stage renal disease in Europe – these patients could benefit from regular PromarkerD testing to enable early detection and intervention to prevent or delay disease progression
Company Notes
Proteomics International Managing Director Dr Richard Lipscombe commented:
“Eurobio Scientific’s extensive distribution network across France ensures that our innovative PromarkerD predictive test can reach healthcare providers efficiently. Eurobio Scientific’s strong relationships with key stakeholders, robust market knowledge and local expertise will drive demand for our test in this important market.”
Full ASX Announcement: 2924-02820052-6A1212669 (markitdigital.com)